Lyell Immunopharma, Inc. (NASDAQ:LYEL) Stock Has Consensus Price Target of $40.86

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has been given an average rating of “Moderate Buy” by the nine research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $40.86.

Several research firms have recently weighed in on LYEL. Stifel Nicolaus started coverage on Lyell Immunopharma in a research report on Thursday, August 6th. They issued a “buy” rating and a $36.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating on shares of Lyell Immunopharma in a research note on Friday, September 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Thursday, October 15th. Citigroup reiterated a “market outperform” rating on shares of Lyell Immunopharma in a research report on Friday, August 14th. Finally, Royal Bank Of Canada set a $34.00 target price on shares of Lyell Immunopharma in a report on Friday, August 14th.

Institutional Trading of Lyell Immunopharma

A number of large investors have recently bought and sold shares of LYEL. Opaleye Management Inc. raised its stake in shares of Lyell Immunopharma by 334.9% in the second quarter. Opaleye Management Inc. now owns 344,025 shares of the company’s stock valued at $4,834,000 after buying an additional 264,928 shares during the period. venBio Partners LLC bought a new position in shares of Lyell Immunopharma during the 2nd quarter worth $4,744,643. Renaissance Technologies LLC increased its holdings in Lyell Immunopharma by 194.8% in the 1st quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock worth $2,335,000 after acquiring an additional 76,921 shares during the last quarter. Velan Capital Investment Management LP increased its holdings in Lyell Immunopharma by 2.9% in the 2nd quarter. Velan Capital Investment Management LP now owns 105,000 shares of the company’s stock worth $1,475,000 after acquiring an additional 3,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in Lyell Immunopharma in the 1st quarter valued at about $959,000. 66.05% of the stock is owned by hedge funds and other institutional investors.

Lyell Immunopharma Stock Down 0.9%

Shares of NASDAQ LYEL opened at $9.31 on Tuesday. Lyell Immunopharma has a twelve month low of $7.20 and a twelve month high of $45.00. The firm has a fifty day simple moving average of $11.36 and a 200 day simple moving average of $17.17. The company has a market capitalization of $228.09 million, a PE ratio of -0.73 and a beta of -0.03.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.92) EPS for the quarter, beating analysts’ consensus estimates of ($1.94) by $0.02. The business had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.00 million. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. As a group, equities analysts expect that Lyell Immunopharma will post -7.16 earnings per share for the current fiscal year.

About Lyell Immunopharma

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell’s research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.